Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant plus ondansetron versus ondansetron alone for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
NL-OMON42702Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant and ondansetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Merck & Co. Primary endpoint: Complete Response in delayed phase. Started Mar 2016; status: recruiting.
02
Drugs
fosaprepitantondansetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON42702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42702.